Literature DB >> 2879471

Tertatolol preserves renal perfusion in patients with arterial hypertension after head injury.

M Leeman, R Naeije, J P Degaute, F Brackman, J Thomas, J F Prost.   

Abstract

Tertatolol is a noncardioselective beta-adrenergic blocking agent without partial agonist activity. Its central and renal hemodynamic effects were compared to those of an equipotent dosage of propranolol in two groups of 10 patients each who developed arterial hypertension and a hyperdynamic circulatory state after head injury. After tertatolol, 5 mg orally, mean arterial blood pressure was unaffected, heart rate decreased by 22% (p less than 0.01) and cardiac index by 24% (p less than 0.01) while renal blood flow remained unchanged (-5%; not significant) so that the renal fraction of cardiac index was increased by 22% (p less than 0.05). After propranolol, 160 mg orally, mean arterial blood pressure was not modified, heart rate decreased by 12% (p less than 0.01), cardiac index by 16% (p less than 0.01) and renal blood flow by 17% (p less than 0.01) so that the renal fraction of cardiac index remained unchanged (-3%; not significant). Tertatolol is a potent beta-blocking agent comparable to propranolol apart from the fact that it preserves renal perfusion; this peculiar effect is related to a redistribution of the reduced cardiac output to the benefit of the kidney.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2879471     DOI: 10.1159/000167331

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  2 in total

Review 1.  Pharmacology of antihypertensive agents with multiple actions.

Authors:  P A van Zwieten
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Stereoselective binding of tertatolol and of 4-hydroxytertatolol to human plasma proteins.

Authors:  G Bastian; S Urien; F Brée; P Jolliet; I Rocher; O Crambes; J P Tillement
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jul-Sep       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.